JPRN-UMIN000044101已完成未知
A multi-institutional retrospective study of osimertinib for elderly patients with previously untreated advanced non-small cell lung cancer harboring EGFR mutations (HOT2002) - HOT2002
Hokkaido Lung Cancer Clinical Study Group(HOT)0 个研究点目标入组 132 人开始时间: 2021年5月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 132
研究概览
简要总结
This study investigated the effects of osimertinib in 132 elderly non-small cell lung cancer patients aged 75 or older. The 1-year progression-free survival rate was 65.8%, with a median duration of 19.4 months. 17.4% of patients experienced severe pneumonitis, mostly within three months of treatment initiation. While osimertinib is effective, there's a notable risk of pneumonitis.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who had received other EGFR-TKIs before receiving osimertinib were excluded.
研究者
相似试验
已完成
不适用
Retrospective observational study of osimertinib and afatinib for patients with advanced EGFR-mutated non-small cell lung cancer.JPRN-UMIN000041251Central Japan Lung Study Group (CJLSG)557
招募中
不适用
Efficacy of Osimertinib in Patients With Lung CancerAdvanced Non-Small Cell Lung CancerNCT06174857Hunan Province Tumor Hospital100
进行中（未招募）
2 期
Osimertinib In EGFR Mutant Lung CancerCarcinoma, Non-Small-Cell LungNCT03586453Dana-Farber Cancer Institute30
已完成
不适用
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positiveNon Small Cell Lung CancerNCT03790397Fundación GECP169
招募中
3 期
Multi-institutional study of Osimertinib dose-optimization with regression discontinuity design in Non-small cell lung cancer patients with Epidermal Growth Factor Receptor activating mutation aged 70 Years or olderJPRN-UMIN000051460Public Health Research Foundation550